Calliditas has applied for accelerated approval, and the FDA will now have up to 60 days to accept the NDA submission and to decide whether Nefecon will receive a priority review.
If a priority review is granted, we believe that an accelerated approval could occur in November (2+6 months from now).
We reiterate our Base case of SEK 280 per share.
Aktuellt
SENASTE
